| Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation HJ Zhu, X Wang, BE Gawronski, BJ Brinda, DJ Angiolillo, JS Markowitz Journal of Pharmacology and Experimental Therapeutics 344 (3), 665-672, 2013 | 198 | 2013 |
| Differences in metabolite profile between blood plasma and serum L Liu, J Aa, G Wang, B Yan, Y Zhang, X Wang, C Zhao, B Cao, J Shi, M Li, ... Analytical biochemistry 406 (2), 105-112, 2010 | 174 | 2010 |
| GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy M Li, X Wang, J Aa, W Qin, W Zha, Y Ge, L Liu, T Zheng, B Cao, J Shi, ... American Journal of Physiology-Renal Physiology 304 (11), F1317-F1324, 2013 | 108 | 2013 |
| Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender J Shi, X Wang, JH Nguyen, BE Bleske, Y Liang, L Liu, HJ Zhu Biochemical pharmacology 119, 76-84, 2016 | 107 | 2016 |
| Metabolomics and its application to the evaluation of the efficacy and toxicity of traditional Chinese herb medicines J Shi, B Cao, XW Wang, JY Aa, JA Duan, XX Zhu, GJ Wang, CX Liu Journal of Chromatography B 1026, 204-216, 2016 | 84 | 2016 |
| Label-free absolute protein quantification with data-independent acquisition B He, J Shi, X Wang, H Jiang, HJ Zhu Journal of proteomics, 2019 | 70 | 2019 |
| Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation J Shi, X Wang, J Nguyen, AH Wu, BE Bleske, HJ Zhu Drug Metabolism and Disposition 44 (4), 554-559, 2016 | 70 | 2016 |
| Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes J Shi, X Wang, L Lyu, H Jiang, HJ Zhu Drug metabolism and pharmacokinetics 33 (2), 133-140, 2018 | 59 | 2018 |
| GC–TOFMS analysis of metabolites in adherent MDCK cells and a novel strategy for identifying intracellular metabolic markers for use as cell amount indicators in data normalization B Cao, J Aa, G Wang, X Wu, L Liu, M Li, J Shi, X Wang, C Zhao, T Zheng, ... Analytical and bioanalytical chemistry 400, 2983-2993, 2011 | 58 | 2011 |
| Metabolic phenotype of rats exposed to heroin and potential markers of heroin abuse T Zheng, L Liu, J Aa, G Wang, B Cao, M Li, J Shi, X Wang, C Zhao, R Gu, ... Drug and alcohol dependence 127 (1-3), 177-186, 2013 | 57 | 2013 |
| Genome-wide pQTL analysis of protein expression regulatory networks in the human liver B He, J Shi, X Wang, H Jiang, HJ Zhu BMC biology 18, 1-16, 2020 | 54 | 2020 |
| CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors X Wang, G Wang, J Shi, J Aa, R Comas, Y Liang, HJ Zhu The pharmacogenomics journal 16 (3), 220-230, 2016 | 51 | 2016 |
| Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms J Shi, X Wang, RF Eyler, Y Liang, L Liu, BA Mueller, HJ Zhu Basic & clinical pharmacology & toxicology 119 (6), 555-561, 2016 | 44 | 2016 |
| Gas chromatography time-of-flight mass spectrometry based metabolomic approach to evaluating toxicity of triptolide J Aa, F Shao, G Wang, Q Huang, W Zha, B Yan, T Zheng, L Liu, B Cao, ... Metabolomics 7, 217-225, 2011 | 43 | 2011 |
| Development of a systematic approach to rapid classification and identification of notoginsenosides and metabolites in rat feces based on liquid chromatography coupled triple … R Xing, L Zhou, L Xie, K Hao, T Rao, Q Wang, W Ye, H Fu, X Wang, ... Analytica chimica acta 867, 56-66, 2015 | 42 | 2015 |
| In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites Y Qian, X Wang, JS Markowitz Drug Metabolism and Disposition 47 (5), 465-472, 2019 | 40 | 2019 |
| Comparative proteomics analysis of human liver microsomes and S9 fractions X Wang, B He, J Shi, Q Li, HJ Zhu Drug metabolism and disposition 48 (1), 31-40, 2020 | 38 | 2020 |
| Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin‐converting enzyme inhibitors after myocardial infarction: a proof‐of‐concept study KE Kristensen, HJ Zhu, X Wang, GH Gislason, C Torp‐Pedersen, ... Clinical Pharmacology & Therapeutics 96 (6), 713-722, 2014 | 34 | 2014 |
| Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment J Aa, L Yu, M Sun, L Liu, M Li, B Cao, J Shi, J Xu, L Cheng, J Zhou, ... Metabolomics 8, 164-173, 2012 | 34 | 2012 |
| Pharmacokinetic interactions between 20 (S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo J Shi, B Cao, W Zha, X Wu, L Liu, W Xiao, R Gu, R Sun, X Yu, T Zheng, ... Acta Pharmacologica Sinica 34 (10), 1349-1358, 2013 | 28 | 2013 |
